Literature DB >> 3119578

The state of ferriprotoporphyrin IX in malaria pigment.

C D Fitch1, P Kanjananggulpan.   

Abstract

To evaluate the state of ferriprotoporphyrin IX (FP) in malaria pigment, mouse erythrocytes infected with Plasmodium berghei NYU-2 parasites were lysed by hypotonic shock, and hemoglobin and other soluble material were removed by extensive washing. The amount of FP recovered in the insoluble pellet was 2.1 mumol/ml of packed infected erythrocytes, of which approximately 1% was attributable to hemoglobin contamination. This crude preparation then was digested with a nonspecific protease from Streptomyces griseus and extracted with chloroform/methanol. The residue of insoluble dark brown material had the spectral and solubility properties characteristic of the FP of malaria pigment, and various different preparations contained from 82 to 99% of FP by weight. By elemental analysis, highly purified preparations contained no chlorine and had an oxygen content consistent with 1 mol of hydroxyl/mol of FP (oxygen content: calculated, 12.6%; found, 12.5%). In comparison to hematin purchased from Sigma, which had a measured oxygen content of 14.7%, the low oxygen form of hematin purified from malaria pigment was remarkably less soluble in ethanol, 3% sodium bicarbonate, and chloroform.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3119578

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  On the preparation of beta-haematin.

Authors:  G Blauer; M Akkawi
Journal:  Biochem J       Date:  2000-03-01       Impact factor: 3.857

2.  Lipophilic mediated assays for beta-hematin inhibitors.

Authors:  Melissa D Carter; Vanessa V Phelan; Rebecca D Sandlin; Brian O Bachmann; David W Wright
Journal:  Comb Chem High Throughput Screen       Date:  2010-03       Impact factor: 1.339

3.  Digital phantoms generated by spectral and spatial light modulators.

Authors:  Bonghwan Chon; Fuyuki Tokumasu; Ji Youn Lee; David W Allen; Joseph P Rice; Jeeseong Hwang
Journal:  J Biomed Opt       Date:  2015       Impact factor: 3.170

Review 4.  Hemozoin biocrystallization in Plasmodium falciparum and the antimalarial activity of crystallization inhibitors.

Authors:  Ernst Hempelmann
Journal:  Parasitol Res       Date:  2006-11-17       Impact factor: 2.289

5.  The neutral lipid composition present in the digestive vacuole of Plasmodium falciparum concentrates heme and mediates β-hematin formation with an unusually low activation energy.

Authors:  Anh N Hoang; Rebecca D Sandlin; Aneesa Omar; Timothy J Egan; David W Wright
Journal:  Biochemistry       Date:  2010-11-08       Impact factor: 3.162

Review 6.  On the mechanisms involved in biological heme crystallization.

Authors:  Renata Stiebler; Juliana B R Correa Soares; Bruno L Timm; José Roberto Silva; Flavia B Mury; Marilvia Dansa-Petretski; Marcus F Oliveira
Journal:  J Bioenerg Biomembr       Date:  2011-02       Impact factor: 2.945

7.  Glutathione-deficient Plasmodium berghei parasites exhibit growth delay and nuclear DNA damage.

Authors:  Vivian Padín-Irizarry; Emilee E Colón-Lorenzo; Joel Vega-Rodríguez; María Del R Castro; Ricardo González-Méndez; Sylvette Ayala-Peña; Adelfa E Serrano
Journal:  Free Radic Biol Med       Date:  2016-03-04       Impact factor: 7.376

8.  Heme and blood-feeding parasites: friends or foes?

Authors:  Shu Qin Toh; Amber Glanfield; Geoffrey N Gobert; Malcolm K Jones
Journal:  Parasit Vectors       Date:  2010-11-18       Impact factor: 3.876

9.  Increase on the initial soluble heme levels in acidic conditions is an important mechanism for spontaneous heme crystallization in vitro.

Authors:  Renata Stiebler; Anh N Hoang; Timothy J Egan; David W Wright; Marcus F Oliveira
Journal:  PLoS One       Date:  2010-09-13       Impact factor: 3.240

10.  Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases.

Authors:  Marina Tiemi Shio; Marina Tiemi Shio; Stephanie C Eisenbarth; Myriam Savaria; Adrien F Vinet; Marie-Josée Bellemare; Kenneth W Harder; Fayyaz S Sutterwala; D Scott Bohle; Albert Descoteaux; Richard A Flavell; Martin Olivier
Journal:  PLoS Pathog       Date:  2009-08-21       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.